Recombination sequence (RS) rearrangement frequency as a measure of central B cell tolerance
View Patent ↗The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions.
1. A method of diagnosing an autoimmune disease in a mammal, the method comprising obtaining DNA from a blood sample obtained from the mammal; measuring the frequency of recombination sequence (RS) rearrangement in the DNA obtained from the mammal; and calibrating the measured frequency of RS rearrangement by at least one of B cell fraction and κ/λ ratio in the blood sample, wherein a reduced level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal is an indication that said mammal has an autoimmune disease.
2. The method of claim 1 , wherein the reduced level of RS rearrangement confers an increased risk of the future development of autoimmunity.
3. The method of claim 1 , wherein said autoimmune disease is type 1 diabetes.
4. The method of claim 1 , wherein said autoimmune disease is systemic lupus erythematosus (SLE).
5. The method of claim 1 , wherein said mammal is a human.
6. The method of claim 1 , wherein said RS rearrangement is measured based on quantitative PCR.
7. A method of diagnosing an autoimmune disease in a mammal, the method comprising obtaining DNA from a blood sample obtained from the mammal; measuring the frequency of recombination sequence (RS) rearrangement in the DNA obtained from the mammal; and calibrating the measured frequency of RS rearrangement by at least one of B cell fraction and κ/λ ratio in the blood sample, without the use of flow cytometry, wherein a reduced level of RS rearrangement compared to the level of RS rearrangement in an otherwise identical healthy mammal is an indication that said mammal has an autoimmune disease.